Related Experiment Video

Updated: Jun 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician

Renato D Lopes1, Jonathan P Piccini, Elaine M Hylek

  • 1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA.

Journal of Thrombosis and Thrombolysis
|September 23, 2008
PubMed

Insights

Atrial fibrillation (AF) increases stroke risk significantly, especially in older adults. This review covers guideline-based antithrombotic therapy to prevent AF-related thromboembolic events and improve patient outcomes.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
  • It accounts for a significant portion of hospitalizations related to heart rhythm disorders.
  • AF poses a substantial risk for thromboembolic complications, particularly stroke.

Purpose of the Study:

  • To review current American College of Cardiology/American Heart Association/European Society of Cardiology guidelines for antithrombotic therapy in AF patients.
  • To discuss future directions in managing antithrombotic treatment for AF.
  • To provide practical insights into effective treatment strategies for AF.

Main Methods:

  • Review of recent clinical guidelines from major cardiology societies.
  • Analysis of epidemiological data on AF incidence and stroke risk.
  • Synthesis of evidence on the efficacy of antithrombotic therapies.

Main Results:

  • Stroke risk in AF patients escalates dramatically with age, from 1.5% in 50-59 year olds to 23% in 80-89 year olds.
  • Ischemic strokes due to AF are associated with a doubled mortality risk compared to other stroke causes.
  • Effective implementation of antithrombotic therapy remains a challenge despite its proven benefits.

Conclusions:

  • Antithrombotic therapy is crucial for preventing stroke in AF patients.
  • Adherence to updated guidelines is essential for optimizing patient care.
  • Further research and improved clinical practice are needed to enhance the management of AF-related thromboembolic risk.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...